Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: D.J.Smyth who wrote (664)	5/5/1998 11:10:00 AM
From: PK	Read Replies (3) \| Respond to of 2135

Even after so many downgrades, ENMD is not falling to earth. I think stock will go higher after the dust settles and the analysts who downgraded have stuffed themselves with cheap shares... Just a thought...

To: D.J.Smyth who wrote (664)	5/5/1998 11:22:00 AM
From: Jason	Read Replies (2) \| Respond to of 2135

ENMD with 5.9 million shares float at the current price 47 is priced at 277 million only. Just think about the money is being spent on research by all big pharmaceutical companies in this area. Instead of spending billions on research why not buy ENMD at a fraction of research money while it is extremely cheap relative to what might offer in the bag? Its potential is priceless....